Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives

Angelis Konstantinopoulos; Konstantinos Giannitsas; Spiros Raptis; Petros Perimenis

doi:10.33393/dti.2007.1310

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives

Authors

Angelis Konstantinopoulos Department of Urology, University Hospital of Patras, Greece.
Konstantinos Giannitsas Department of Urology, University Hospital of Patras, Greece.
Spiros Raptis Department of Urology, University Hospital of Patras, Greece.
Petros Perimenis Department of Urology, University Hospital of Patras, Greece.

DOI:

https://doi.org/10.33393/dti.2007.1310

Keywords:

Endothelial dysfunction, erectile dysfunction, phosphodiesterase 5 inhibitors

Abstract

Endothelial dysfunction is a pathological entity that multiply affects the health status. Erectile dysfunction is being recognized as a condition that is strongly interrelated with endothelial dysfunction, being a vascular event itself. Oral pharmacotherapy for erectile dysfunction has provided us with a new armamentarium on this condition. Phosphodiesterase 5 inhibitors have been investigated and proved useful in clinical practice for erectile dysfunction but in addition to this, the results seem promising of a beneficial effect on endothelial dysfunction, as well.

Downloads

Download data is not yet available.

Downloads

Published

2007-01-01

How to Cite

Konstantinopoulos, A., Giannitsas, K., Raptis, S., & Perimenis, P. (2007). Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives. Drug Target Insights, 2(1). https://doi.org/10.33393/dti.2007.1310